Jefferies Financial Group Inc. lifted its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 38.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 417,500 shares of the financial services provider’s stock after purchasing an additional 115,194 shares during the quarter. iShares Biotechnology ETF accounts for about 0.6% of Jefferies Financial Group Inc.’s portfolio, making the stock its 12th biggest position. Jefferies Financial Group Inc. owned about 0.79% of iShares Biotechnology ETF worth $87,896,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of IBB. Bank of America Corp DE grew its position in shares of iShares Biotechnology ETF by 10.8% in the 1st quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock valued at $1,225,767,000 after purchasing an additional 707,343 shares during the period. Royal Bank of Canada lifted its stake in iShares Biotechnology ETF by 1.0% in the first quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock valued at $124,464,000 after buying an additional 7,434 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in iShares Biotechnology ETF by 1.3% in the third quarter. Commonwealth Equity Services LLC now owns 139,653 shares of the financial services provider’s stock valued at $29,401,000 after buying an additional 1,819 shares in the last quarter. Albion Financial Group UT boosted its holdings in shares of iShares Biotechnology ETF by 1.0% in the third quarter. Albion Financial Group UT now owns 120,782 shares of the financial services provider’s stock valued at $25,428,000 after buying an additional 1,147 shares during the period. Finally, Cetera Investment Advisers boosted its holdings in shares of iShares Biotechnology ETF by 9.4% in the first quarter. Cetera Investment Advisers now owns 128,530 shares of the financial services provider’s stock valued at $21,702,000 after buying an additional 10,994 shares during the period. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
Shares of NASDAQ:IBB opened at $218.14 on Thursday. iShares Biotechnology ETF has a 12 month low of $159.68 and a 12 month high of $222.29. The company’s fifty day simple moving average is $208.98 and its 200 day simple moving average is $186.54.
iShares Biotechnology ETF Cuts Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. This is a drop from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. The ex-dividend date was Tuesday, September 15th. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%.
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
